RIGL Stock Analysis: Rigel Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 863m USD | 12M Return: 67.9% | US7665597024 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.90M
Qual. Beats: 0
Rev. Trend: 94.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rigel Pharmaceuticals is a U.S.-based biotechnology company that develops and commercializes therapies for hematologic disorders and cancer. The company markets three approved products: TAVALISSE (fostamatinib) for chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for relapsed/refractory IDH1-mutated acute myeloid leukemia, and GAVRETO (pralsetinib) for RET fusion-positive non-small cell lung cancer and thyroid cancer. GAVRETO is part of a global collaboration with Roche, reflecting a common biotech business model in which smaller companies partner with larger pharmaceutical firms to co-develop and commercialize targeted oncology therapies.
Beyond its commercial portfolio, Rigel is advancing a clinical pipeline that includes R289, an oral IRAK1/4 inhibitor being studied in hematology-oncology, autoimmune, and inflammatory indications. The company also maintains research collaborations with The University of Texas MD Anderson Cancer Center and the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT) to explore olutasidenib in additional IDH1-mutated cancers. Incorporated in 1996 and headquartered in South San Francisco, Rigel operates within the broader biotechnology sector, where companies typically depend on a mix of product revenue, partnerships, and pipeline development to sustain long-term growth.
- REZLIDHIA and TAVALISSE net product sales growth trajectory
- R289 Phase 1b readout in lower-risk MDS approaches
- Cash burn raises potential dilutive capital raise risk
| Net Income: 321.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA -16.59 > 1.0 |
| NWC/Revenue: 32.58% < 20% (prev 33.13%; Δ -0.55% < -1%) |
| CFO/TA 0.15 > 3% & CFO 79.4m > Net Income 321.9m |
| Net Debt (-54.7m) to EBITDA (94.0m): -0.58 < 3 |
| Current Ratio: 1.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.6m) vs 12m ago 7.75% < -2% |
| Gross Margin: 91.39% > 18% (prev 91.52%; Δ -0.13% > 0.5%) |
| Asset Turnover: 76.06% > 50% (prev 129.6%; Δ -53.54% > 0%) |
| Interest Coverage Ratio: 15.74 > 6 (EBIT TTM 91.4m / Interest Expense TTM 5.80m) |
| A: 0.17 (Total Current Assets 185.5m - Total Current Liabilities 95.4m) / Total Assets 521.1m |
| B: -1.91 (Retained Earnings -997.1m / Total Assets 521.1m) |
| C: 0.25 (EBIT TTM 91.4m / Avg Total Assets 363.9m) |
| D: 4.46 (Book Value of Equity 425.4m / Total Liabilities 95.4m) |
| Altman-Z'' = 1.27 = BB |
| DSRI: 1.36 (Receivables 56.0m/39.9m, Revenue 276.8m/267.9m) |
| GMI: 1.00 (GM 91.52% / 91.39%) |
| AQI: 4.41 (AQ_t 0.64 / AQ_t-1 0.15) |
| SGI: 1.03 (Revenue 276.8m / 267.9m) |
| TATA: 0.47 (NI 321.9m - CFO 79.4m) / TA 521.1m) |
| Beneish M = -0.63 (Cap -4..+1) = D |
As of September 27, 2026, the stock is trading at USD 48.18 with a total of 204,929 shares traded. Over the past week, the price has changed by +3.30%, over one month by +3.06%, over three months by +30.25% and over the past year by +67.87%.
Current recommended Stop Loss: 46.10 (which is 4.3% or 1.2 ATR below the current price).
Rigel Pharmaceuticals has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold RIGL.
- StrongBuy: 1
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 63 | 30.8% |
P/E Trailing = 2.7275
P/E Forward = 8.7184
P/S = 3.1477
P/B = 2.0141
P/EG = -0.1
Revenue TTM = 276.8m USD
EBIT TTM = 91.4m USD
EBITDA TTM = 94.0m USD
Long Term Debt = 22.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 39.9m USD (from shortTermDebt, last quarter)
Debt = 40.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 714k
Net Debt = -54.7m USD (calculated: Debt 40.7m - CCE 95.3m)
Enterprise Value = 808.3m USD (862.9m + Debt 40.7m - CCE 95.3m)
Interest Coverage Ratio = 15.74 (Ebit TTM 91.4m / Interest Expense TTM 5.80m)
EV/FCF = 10.18x (Enterprise Value 808.3m / FCF TTM 79.4m)
FCF Yield = 9.82% (FCF TTM 79.4m / Enterprise Value 808.3m)
FCF Margin = 28.68% (FCF TTM 79.4m / Revenue TTM 276.8m)
Net Margin = 116.3% (Net Income TTM 321.9m / Revenue TTM 276.8m)
Gross Margin = 91.39% ((Revenue TTM 276.8m - Cost of Revenue TTM 23.8m) / Revenue TTM)
Gross Margin QoQ = 89.17% (prev 92.17%)
Tobins Q-Ratio = 1.55 (Enterprise Value 808.3m / Total Assets 521.1m)
Interest Expense / Debt = 14.28% (Interest Expense 5.80m / Debt 40.7m)
Taxrate = 26.69% (6.29m / 23.6m)
NOPAT = 67.0m (EBIT 91.4m * (1 - 26.69%))
Current Ratio = 1.95 (Total Current Assets 185.5m / Total Current Liabilities 95.4m)
Debt / Equity = 0.10 (Debt 40.7m / totalStockholderEquity, last quarter 425.4m)
Debt / EBITDA = -0.58 (Net Debt -54.7m / EBITDA 94.0m)
Debt / FCF = -0.69 (Net Debt -54.7m / FCF TTM 79.4m)
Total Stockholder Equity = 333.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 88.46% (Net Income 321.9m / Total Assets 521.1m)
RoE = 96.49% (Net Income TTM 321.9m / Total Stockholder Equity 333.6m)
RoCE = 25.66% (EBIT 91.4m / Capital Employed (Equity 333.6m + L.T.Debt 22.5m))
RoIC = 14.83% (NOPAT 67.0m / Invested Capital 451.8m)
WACC = 9.49% (E(862.9m)/V(903.6m) * Re(9.44%) + D(40.7m)/V(903.6m) * Rd(14.28%) * (1-Tc(0.27)))
Discount Rate = 9.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.36 | Cagr: 5.04%
[DCF] Terminal Value 74.38% ; FCFF base≈73.9m ; Y1≈84.8m ; Y5≈124.8m
[DCF] Fair Price = 87.50 (EV 1.56b - Net Debt -54.7m = Equity 1.62b / Shares 18.5m; r=9.49% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.04 | # QB: 0
Revenue Correlation: 94.76 | Revenue CAGR: 48.83% | SUE: 2.28 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.96 | Chg30d=+8.75% | Revisions=-57% | Analysts=4
EPS current Year (2026-12-31): EPS=3.54 | Chg30d=+3.28% | Revisions=-29% | GrowthEPS=-44.9% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=4.94 | Chg30d=+12.40% | Revisions=+0% | GrowthEPS=+39.4% | GrowthRev=+21.9%
[Analyst] Revisions Ratio: -40% (up=3, down=9)